Frontopolar tDCS to improve safety learning and extinction in OCD
Official title: Characterization and Modulation of Functional Connectivity and Fear Extinction Abnormalities in Obsessive-Compulsive Disorder
Run by Yale University · NCT06834217 · Data updated 2026-11-12
This will test whether brief frontopolar transcranial direct current stimulation (tDCS) can help adults with OCD improve extinction learning and safety-signal processing.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | Yale University Academic / other |
| Locations | 1 site (New Haven, Connecticut) |
| Status | Recruiting |
| Started | September 12, 2025 |
| Main results expected | April 1, 2029 |
| Study ends | August 1, 2029 |
| Registry record updated | July 23, 2026 |
| Trial ID | NCT06834217 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 or older with a primary diagnosis of OCD, at least one year of symptoms, currently symptomatic, and on stable or no psychiatric treatment for at least eight weeks would be eligible.
✕Probably not a fit
People with bipolar disorder, psychotic disorders, active severe substance use, major neurological disease, significant traumatic brain injury, pregnancy, or other excluded conditions are unlikely to be eligible or to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will enroll 180 adults (120 with OCD, 60 matched controls) for a three-day, in-person experiment combining fMRI, fear-conditioning/extinction tasks, and physiological measures such as skin conductance and threat-expectancy ratings. On day 1 participants undergo structural and resting-state fMRI and Pavlovian conditioning to establish fear and safety cues. On day 2 OCD participants are randomized, double-blind, to receive either active or sham frontopolar tDCS during extinction training. The team will examine whether OCD is linked to dysconnectivity between the default mode and salience networks and whether tDCS normalizes connectivity and improves extinction-related learning and responding.
Why it matters
Potential benefit: If successful, this approach could improve the brain's ability to learn safety during exposure-based treatment and thereby enhance outcomes for people with OCD.
How similar studies have gone: Prior laboratory and small clinical studies have shown that tDCS can modulate learning, memory, and network connectivity, but clinical evidence for lasting benefits in OCD is limited and mixed.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All Participant Inclusion Criteria would include: 1. 18 years of age or older 2. speak English fluently, and 3. able to provide written and verbal informed consent. * Obsessive-compulsive disorder (OCD) Inclusion Criteria would include: 1. meet criteria for OCD as determined by structured clinical interview 2. exhibit significant current symptoms of OCD 3. report duration of OCD symptoms of at least 1-year 4. OCD symptoms are primary or co-primary relative to other psychiatric diagnoses 5. stable psychiatric treatment (≥8-weeks) or no active treatment. 6. exhibit significant current symptoms of OCD as determined by the Dimensional Obsessive-Compulsive Scale (DOCS) (≥18). Exclusion Criteria: * All Participant Exclusion Criteria would include: 1. active severe substance use disorder(s) 2. acute suicidality 3. history of bipolar or psychotic disorder(s) 4. significant developmental disabilities 5. loss of consciousness \> 10 minutes 6. history of traumatic brain injury 7. major neurological disease 8. a positive pregnancy test 9. other brain stimulation or magnetic resonance imaging contraindications 10. new psychological treatment within the past 8 weeks 11. daily anxiolytic medication use (e.g., benzodiazepine). * Non-Clinical Control Exclusion Criteria would include: 1. meet current criteria for a psychiatric disorder as determined by structured clinical interview 2. active-psychotropic medications.
Where it's running
-
Temple Medical Center
New Haven, Connecticut, United States Recruiting
Study contacts
- Study coordinator: Thomas Adams, PhD
- Email: thomas.adamsjr@yale.edu
- Phone: (203) 974-7523
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Focused ultrasound for mood and anxiety disorders
This study tests whether repeated low-intensity focused ultrasound using the ATTN201 device can help people with subsyndromal to moderate depression, anxiety, or OCD.
-
Predicting Treatment Response in Psychiatric Disorders Using Biological Markers
This study tests whether biological markers can predict which patients with psychiatric conditions will respond to treatment.
-
Safety and feasibility of a next-generation dome helmet for neuromodulation in OCD
This study tests whether a new focused ultrasound helmet can safely help people with treatment-refractory OCD see if their symptoms improve.
-
Bergen Four-Day Treatment for OCD, in Finland
This trial tests whether the Bergen Four-Day Treatment for OCD can be implemented in Finnish psychiatric care to help people with OCD see if the intensive program works in a real-world setting.
-
Test different deep TMS coils and targets to treat OCD
This study tests whether different deep TMS coils and brain targets help reduce OCD symptoms in adults with OCD, using a double-blind setup with sham and active stimulation.
-
Role of theta brain waves in how kids control thoughts and actions
This study tests whether theta-frequency brain activity can reveal how children with ADHD or OCD, and healthy kids, manage thinking and behavior during tasks.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.